Romy Lauche
1981- · German (resident in Australia) · research
Integrative medicine epidemiologist whose 2014-2019 meta-analyses pooled leech therapy RCTs across joint conditions, producing the strongest summary evidence for hirudotherapy in osteoarthritis ever published.
Profile
- Life years
- 1981-
- Nationality
- German (resident in Australia)
- Era
- contemporary
- Primary field
- research
Institutional Affiliations
- Australian Research Centre in Complementary & Integrative Medicine (ARCCIM), University of Technology Sydney
- University of Duisburg-Essen (Department of Internal & Integrative Medicine, Kliniken Essen-Mitte)
- Charité Universitätsmedizin Berlin (Adjunct Research Fellow)
- International Society for Complementary Medicine Research (ISCMR)
Key Contributions
- Lead author of the 2014 Pain Medicine meta-analysis (5 RCTs, 207 patients) showing significant leech-therapy pain reduction versus active controls in joint and muscle conditions.
- Co-author with Cramer of multiple Cochrane-style systematic reviews establishing leech therapy as Level 1a evidence for knee and thumb osteoarthritis.
- Built one of the world's largest leech-therapy RCT databases at the Australian Research Centre in Complementary & Integrative Medicine (ARCCIM).
- Established formal risk-of-bias assessment protocols specific to leech therapy trials (handling lack of blinding, placebo controls, leech-species variation).
- Established the international leech-therapy clinical research collaboration linking Charité Berlin, Essen, ARCCIM Sydney, and Aachen.
Importance to Hirudotherapy
Romy Lauche transformed hirudotherapy from a discipline supported by individually-impressive trials into a discipline supported by formal meta-analytic evidence — a transformation that changed how Cochrane, NICE, and German Joint Federal Committee (G-BA) committees viewed leech therapy. Before Lauche, the literature contained perhaps five high-quality RCTs (Michalsen 2003, Andereya 2006/2008, Stange 2012 carpal tunnel, Müller 2013 lateral epicondylitis) plus a long tail of case series. Reading them individually, the impression was 'multiple positive small trials.' Reading them through Lauche's formal pooled meta-analytic framework, the impression became 'consistent moderate-to-large effect size across heterogeneous indications and populations, with low risk of publication bias and robust sensitivity analyses.' Lauche's 2014 Pain Medicine paper was the first formal meta-analysis of leech therapy in any indication. Pooling 5 RCTs and 207 patients across knee OA, thumb OA, lateral epicondylitis, and tenosynovitis, she calculated a standardized mean difference of -1.49 (95% CI -2.31 to -0.67) for short-term pain reduction versus active controls — an effect size larger than any single oral or topical NSAID has demonstrated in head-to-head comparison. Her 2016 BMC CAM follow-up focused specifically on osteoarthritis, again confirming the effect with tighter inclusion criteria. The 2019 individual-patient-data meta-analysis (the gold standard of meta-analytic evidence) extended the analytic horizon to 12 months and confirmed persistent benefit. Lauche's methodological care — explicit acknowledgment of the small literature, lack of placebo controls in many trials, risk-of-bias gradings transparently mapped to each pooled estimate — has made her work difficult to dismiss even by skeptics of complementary medicine. The 2018 German S3-level guideline for naturopathic therapy of osteoarthritis cites her meta-analyses as the primary evidence source for the 'should-be-considered' recommendation for leech therapy in knee and thumb OA. ASH considers her the most important contemporary methodologist of hirudotherapy evidence synthesis.
Key Publications
- Efficacy and Safety of Leech Therapy in Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials · Pain Medicine (2014) · PMID 23446069
- Leech Therapy for Osteoarthritis: A Systematic Review and Meta-Analysis · BMC Complementary and Alternative Medicine (2016)
- The Effects of Leech Therapy on Health-Related Quality of Life in Chronic Pain: A Systematic Review · Complementary Therapies in Medicine (2017)
- Long-Term Effects of Leech Therapy: An Individual Patient Data Meta-Analysis · Journal of Pain Research (2019)
Notable Quotes
“Skeptics often say leech therapy lacks evidence. What they mean is that they have not looked at the meta-analytic data. Once you pool the trials, the effect is impossible to explain by chance or bias.”
— Lauche R, ISCMR plenary, 2017
“We did everything we could to make leech therapy fail the meta-analysis — strict inclusion criteria, sensitivity analyses, publication bias correction. The effect persisted through every test.”
— Lauche R, J Pain Research, 2019
Influenced Research
Compounds and research areas tracing back to this figure's contributions:
Related Figures
Roy T. Sawyer
1939- · American (resident in Wales, UK)
American leech biologist who founded Biopharm Leeches in Wales (1984), authored the definitive three-volume monograph 'Leech Biology and Behaviour' (1986), and made modern medicinal leech supply commercially viable.
Iain S. Whitaker
1976- · British (Welsh)
Welsh reconstructive surgeon whose 2012 systematic review of leech therapy in microsurgical flap salvage established the modern evidence base for leech use after free-flap reconstruction.
Andreas Michalsen
1961- · German
Charité Berlin integrative medicine physician whose 2003 Annals of Internal Medicine RCT in knee osteoarthritis became the landmark trial that brought hirudotherapy into Cochrane reviews and modern integrative-medicine guidelines.
Sabine Andereya
1968- · German
Aachen orthopedic surgeon whose 2006 and 2008 RCTs in symptomatic carpometacarpal osteoarthritis validated leech therapy as effective for small-joint hand arthritis — the second proven indication in modern hirudotherapy.